Researchers at Oregon Health & Science University have developed the first transgenic nonhuman primate model—genetically ...

On 12 Feb 2025, Lion TCR announced that its mRNA-encoded T-cell receptor (TCR)-T cell therapy product Liocyx-M004 has received clearance from the U.S. Food and Drug Administration (FDA) to initiate an ...

Savage resident Edwin Tan spent his summer carrying a message across the triathlon finish line. Tan, 29, lives with chronic hepatitis B. He said there isn’t a lot of public ...

GSK is prioritizing development of its hepatitis B treatment bepirovirsen as the pharma ends work on another potential ...

Existing treatment criteria for chronic hepatitis B virus (HBV) infection are mainly based on data from observational studies, such as the REVEAL study from Taiwan, which was initiated in the early ...

Notably, the new guidelines also addressed health disparities, advocating for equitable access to HBV prophylaxis, monitoring, and treatment. The authors noted some persisting knowledge gaps in ...

Course- based Undergraduate Research Experiences (CUREs) by incorporating nine essential elements of research, relevance, scientific background, hypothesis development, research proposal, all aspects ...

A "groundbreaking" £1.65 million treatment has been approved for use on the NHS, offering patients with severe sickle cell disease some hope of a cure. It is believed around 1,700 people could be ...

High-impact interventions to prevent, diagnose and treat viral hepatitis exist, including vaccines and effective treatments for HBV and a cure for HCV. The COVID-19 pandemic further exposed the ...

The recovery can extend from anywhere between six to 12 months and occasionally up to three years. Currently, there is no certain cure for Guillain-Barré Syndrome. The paralysis not only affects the ...

Famciclovir. A prodrug of penciclovir, famciclovir does not have a major role in the treatment of chronic hepatitis B because of its low efficacy compared with lamivudine. Adefovir dipivoxil.

An antisense drug developed by GlaxoSmithKline has been shown to suppress the hepatitis B virus (HBV) in a phase 2 trial, raising hopes of a “functional cure” for the widespread disease.